Tag Archives: Enlivex Therapeutics

H.C. Wainwright Reiterates Their Buy Rating on Enlivex Therapeutics (ENLV)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Enlivex Therapeutics (ENLV – Research Report), with a price target of $33.00. The company’s shares closed last Tuesday at $9.80. According to TipRanks.com, Selvaraju is

H.C. Wainwright Keeps Their Buy Rating on Enlivex Therapeutics (ENLV)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Enlivex Therapeutics (ENLV – Research Report), with a price target of $33.00. The company’s shares closed last Friday at $9.74. According to TipRanks.com, Selvaraju is

Analysts Offer Insights on Healthcare Companies: Enlivex Therapeutics (NASDAQ: ENLV), Collplant Holdings (NASDAQ: CLGN) and Satsuma Pharmaceuticals (NASDAQ: STSA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enlivex Therapeutics (ENLV – Research Report), Collplant Holdings (CLGN – Research Report) and Satsuma Pharmaceuticals (STSA – Research Report) with bullish sentiments.

Analysts Offer Insights on Healthcare Companies: Enlivex Therapeutics (NASDAQ: ENLV) and Electrocore (NASDAQ: ECOR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Enlivex Therapeutics (ENLV – Research Report) and Electrocore (ECOR – Research Report) with bullish sentiments. Enlivex Therapeutics (ENLV) H.C. Wainwright analyst Ram

Analysts Are Bullish on Top Healthcare Stocks: Enlivex Therapeutics (ENLV), Ascendis Pharma (ASND)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enlivex Therapeutics (ENLV – Research Report), Ascendis Pharma (ASND – Research Report) and Ocular Therapeutix (OCUL – Research Report) with bullish sentiments.

H.C. Wainwright Thinks Enlivex Therapeutics’ Stock is Going to Recover

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Enlivex Therapeutics (ENLV – Research Report), with a price target of $22.00. The company’s shares closed last Monday at $5.60, close to its 52-week low